共 50 条
- [31] A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "Gatekeeper" Mutant of Bcr-AblJOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (15) : 5439 - 5448Choi, Hwan GeunRen, PingdaAdrian, FranciscoSun, FangxianLee, Hyun SooWang, XiaDing, QiangZhang, GuobaoXie, YongpingZhang, JianmingLiu, YiTuntland, ToveWarmuth, MarkusManley, Paul W.Mestan, JuergenGray, Nathanael S.Sim, Taebo
- [32] The molecular signature of BCR::ABL P210 and BCR::ABL T315I in a Drosophila melanogaster chronic leukemia modelISCIENCE, 2024, 27 (04)Baassiri, AmroGhais, AliKurdi, AbdallahRahal, EliasNasr, RihabShirinian, Margret
- [33] Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemiaLEUKEMIA RESEARCH, 2019, 76 : 87 - 93Kang, Ki-HoonKim, Soo-HyunChoi, Soo-YoungYoo, Hae-LyunLee, Mi-YoungSong, Hye-YoungKee, Kyung-MiSuh, Ji-HyungYang, Seon-YoungJang, Eun-JungLee, Sung-EunKim, Dong-Wook
- [34] Electronic and structural study of T315I mutated form in DFG-out conformation of BCR-ABL inhibitorsJOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (20) : 9774 - 9788Pereira, Washington A.Nascimento, Erica C. M.Martins, Joao B. L.
- [35] Derivates of 1,6-dihyadroazaazulenes as inhibitors of tyrosine kinases BCR-ABL1 wild type and mutant T315I: a molecular dynamics approachJOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (24) : 13864 - 13875Solis-Hernandez, Manuel de JesusPalomares-Baez, Juan PedroHerrera-Bucio, RafaelChacon-Garcia, LuisNavarro-Santos, Pedro
- [36] Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I MutationCLINICAL PHARMACOKINETICS, 2024, 63 (09) : 1301 - 1312Combes, Francois PierreSy, Sherwin K. B.Li, Ying FeiLorenzo, SebastienDasgupta, KohinoorKapoor, ShrutiHoch, MatthiasHo, Yu-Yun
- [37] Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutationActaPharmaceuticaSinicaB, 2021, 11 (05) : 1315 - 1328Liang JiangYuting WangQian LiaZhengchao TuSihua ZhuSanfang TuZhang ZhangKe DingXiaoyun Lu
- [38] Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutationCHEMICAL BIOLOGY & DRUG DESIGN, 2021, 97 (03) : 649 - 664Liu, JuanZhang, YuanHuang, HonglinLei, XiaoyongTang, GuotaoCao, XuanPeng, Junmei
- [39] Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutationBRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (03) : 407 - 410Coude, Marie-MagdelaineLuycx, OdileCariou, Marie-EstelleMaarek, OdileDombret, HerveCayuela, Jean-MichelRea, Delphine
- [40] FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I MutationCLINICAL CANCER RESEARCH, 2024, 30 (19) : 4266 - 4271Pamuk, Gulsum E.Chow, Edwin C. Y.Ionan, Alexei C.Chen, HaiyanLee, Shwu-LuanHsu, VickyGrimstein, ManuelaZheng, NanSun, JielinCharlab, RosaneGehrke, Brenda J.Vallejo, JonathonEhrlich, Lori A.de Claro, R. AngeloTheoret, Marc R.